---
schema_version: "secwatch.filing_event.v1"
accession: "0000914121-22-004104"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T04:56:13.146631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q1 sales up 5.9% to $81.5M, GAAP loss $0.33/sh, reaffirms FY2023 outlook

## Summary
- Net sales of $81.5M increased 5.9% YoY; GAAP net loss of $13.0M or $0.33 per share vs $0.18 loss a year ago.
- Med Tech net sales $22.8M (+29.6%), driven by Auryon (+50.0%) and thrombectomy (+31.8%); Med Device declined 1.1% to $58.7M.
- Gross margin 51.9% down 20 bps; adjusted loss per share $0.06 vs $0.02 in prior year.
- FY2023 guidance reaffirmed: net sales $342-348M, gross margin 52.5%-54.5%, adjusted EPS $0.01-$0.06.
- New $75M credit facility with $30M term loan (drawn $25M); cash $24.6M; AlphaVac F18 full market release commenced.

## SEC filing metadata
- accession: 0000914121-22-004104
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000091412122004104/0000914121-22-004104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000091412122004104/an58259826-8ki.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914121-22-004104
- JSON: https://secwatch.observer/filing/0000914121-22-004104.json
- Plain text: https://secwatch.observer/filing/0000914121-22-004104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.